Intraocular pressure reduction with once-a-day application of a new prostaglandin eye drop: a pilot placebo-controlled study in 12 patients.

Ciro CarusoLuigi PacentePasquale TroianoCarmine OstacoloLuca D'AndreaSilvia BartollinoCiro Costagliola

Published in: International ophthalmology (2019)

The travoprost metabolite 15-keto fluprostenol was effective in decrease IOP and maintained IOP reduction along 5 days of treatment. The 15-keto fluprostenol can be developed as a good candidate for once-a-day NTG patients' treatment.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
combination therapy
patient reported